atenolol has been researched along with Bright Disease in 5 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 9.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "A supervised administration of atenolol following hemodialysis effectively and safely controls hypertension in chronic hemodialysis patients." | 5.09 | Supervised atenolol therapy in the management of hemodialysis hypertension. ( Agarwal, R, 1999) |
| "Tertatolol is a new beta-blocker with specific vasodilatory properties, and thus might be particularly useful in CsA-treated transplant recipients." | 2.69 | Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. ( Branten, AJ; Hilbrands, LB; Huysmans, FT; Koene, RA; van Hamersvelt, HW, 1998) |
| "Proteinuria was assessed by urine sampling at the end of each treatment period." | 2.68 | Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis. ( Berger, E; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S, 1996) |
| "Proteinuria was determined in the course of a three-day collection period at the end of each treatment phase." | 2.68 | [Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors]. ( Berger, ED; Braun, N; Erley, CM; Heyne, N; Klass, M; Krämer, D; Risler, T; Wolf, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erley, CM | 2 |
| Klass, M | 2 |
| Krämer, D | 2 |
| Berger, E | 1 |
| Heyne, N | 2 |
| Braun, N | 2 |
| Wolf, S | 2 |
| Risler, T | 2 |
| Berger, ED | 1 |
| Branten, AJ | 1 |
| Hilbrands, LB | 1 |
| van Hamersvelt, HW | 1 |
| Koene, RA | 1 |
| Huysmans, FT | 1 |
| Agarwal, R | 1 |
| Arora, P | 1 |
| Kumar, V | 1 |
| Dubey, NK | 1 |
| Mahesh, K | 1 |
4 trials available for atenolol and Bright Disease
| Article | Year |
|---|---|
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 1996 |
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 1997 |
Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Cross-Over Studies; Cyclosporine; Fema | 1998 |
Supervised atenolol therapy in the management of hemodialysis hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; | 1999 |
1 other study available for atenolol and Bright Disease
| Article | Year |
|---|---|
Nebulised salbutamol: an antidote for beta blockers.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Al | 1999 |